Objective:

To report a unique case of a 2-year-old male with concurrent Evans syndrome (ES) and Mucopolysaccharidosis Type II (MPS II), detailing clinical presentation, genetic findings, treatment outcomes, and implications for clinical practice.

Approach:

Key Findings:

• The patient exhibited severe anemia and thrombocytopenia alongside characteristic MPS II symptoms.
• A novel mutation in the IDS gene was identified, expanding the known mutational spectrum associated with MPS II.
• HSCT effectively normalized IDS enzyme activity and resolved occurrences of ES.

Interpretation:

This case highlights the potential pathogenic relationship between MPS II and hematological disorders, emphasizing the importance of recognizing and managing concurrent conditions, which may influence treatment strategies.

Limitations:

• The rarity of the conditions limits the generalizability of findings.
• Long-term follow-up data is needed to fully assess the outcomes of HSCT in similar cases.
• Further research is required to explore the relationship between MPS II and ES.

Conclusion:

This case is the first documented instance of concurrent ES and MPS II in a young child, demonstrating the effectiveness of HSCT in managing this rare comorbidity and highlighting the need for awareness in clinical practice.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.